Abstract:This graphic abstract provides an overview of the paper, focusing on the neuromodulatory effects of the neuropeptide orexin‐A (OXA) in sepsis‐associated encephalopathy. OXA reduces reactive oxygen species‐induced oxidative stress by inhibiting NOX2 expression in hippocampal tissue. The main mechanism may be by inhibiting the activation of A1‐type astrocytes and microglia with the NF‐κB/ERK signaling pathway, which reduces the expression of pro‐inflammatory factors TNF‐α and IL‐1β and reduces neuronal apoptosis. Background Oxidative stress‐induced inflammation is a major pathogenic mechanism in sepsis‐associated encephalopathy (SAE). We hypothesized that regulation of reactive oxygen species (ROS) by the neuropeptide orexin‐A could prevent SAE‐induced oxidative stress and inflammation. Therefore, the aim of this study was to investigate the effects of orexin‐A on oxidative stress and inflammation in SAE in mice. Methods Adult male mice were treated with orexin‐A (250 μg/kg, intranasal administration) to establish a cecal ligation perforation (CLP) model. We performed behavioral tests, observed neuronal damage in the hippocampal region, measured the levels of ROS, NOX2, and observed the structure of mitochondria by transmission electron microscopy. We then examined the inflammatory factors TNF‐α and IL‐1β, the activation of microglia and astrocytes, the expression of ERK/NF‐κB, C3, and S100A10, and the presence of A1 type astrocytes and A2 type astrocytes. Results Orexin‐A treatment improved cognitive performance in CLP‐induced SAE mice, attenuated neuronal apoptosis in the hippocampal region, ameliorated ROS levels and the extent of mitochondrial damage, and reduced protein expression of NOX2 in hippocampal tissue. In addition, orexin‐A treatment significantly reduced microglia and astrocyte activation, inhibited the levels of P‐ERK and NF‐κB, and reduced the release of IL‐1β and TNF‐α, which were significantly increased after CLP. Finally, Orexin‐A treatment significantly decreased the number of C3/glial fibrillary acidic protein (GFAP)‐positive cells and increased the number of S100A10/GFAP‐positive cells. Conclusion Our data suggest that orexin‐A reduces ROS expression by inhibiting CLP‐induced NOX2 production, thereby attenuating mitochondrial damage and neuronal apoptosis. Its inhibition of microglial and A1‐type astrocyte activation and inflammation was associated with the ERK/NF‐κB pathway. These suggest that orexin‐A may reduce cognitive impairment in SAE by reducing oxidative stress‐induced inflammation.

Role of orexin-A in experimental autoimmune encephalomyelitis

Orexin A, an amphipathic α-helical neuropeptide involved in pleiotropic functions in the nervous and immune systems: Synthetic approach and biophysical studies of the membrane-bound state

Orexin‐A Attenuates the Inflammatory Response in Sepsis‐Associated Encephalopathy by Modulating Oxidative Stress and Inhibiting the ERK/NF‐κB Signaling Pathway in Microglia and Astrocytes

Orexin A alleviates neuroinflammation via OXR2/CaMKKβ/AMPK signaling pathway after ICH in mice

Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses

Orexin A alleviates LPS-induced acute lung injury by inhibiting macrophage activation through JNK-mediated autophagy

Therapeutic effects of orexin-A in sepsis-associated encephalopathy in mice

Oleacein Attenuates the Pathogenesis of Experimental Autoimmune Encephalomyelitis through Both Antioxidant and Anti-Inflammatory Effects

Selective orexin 1 receptor antagonist SB-334867 aggravated cognitive dysfunction in 3xTg-AD mice

Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis

Orexin A induced increases in rat locus coeruleus neuronal activity are attenuated by systemic administration of OX1R and OX2R antagonists

Ozanimod-mediated remission in experimental autoimmune encephalomyelitis is associated with enhanced activity of CNS CD27low/- NK cell subset

Immunoregulation of Experimental Autoimmune Encephalomyelitis by the Selective CB1 Receptor Antagonist.

Oleanolic Acid Acetate Alleviates Symptoms of Experimental Autoimmune Encephalomyelitis in Mice by Regulating Toll-Like Receptor 2 Signaling

Orexin-A exerts neuroprotective effect in experimental intracerebral hemorrhage by suppressing autophagy via OXR1-mediated ERK/mTOR signaling pathway

Selective Orexin 2 Receptor Blockade Alleviates Cognitive Impairments and the Pathological Progression of Alzheimer's Disease in 3xTg-AD Mice

Orexin-A aggravates cognitive deficits in 3xTg-AD mice by exacerbating synaptic plasticity impairment and affecting amyloid β metabolism

The Role of the Orexin System in Craniocerebral Trauma-Induced Epilepsy in Mice

Targeting CB2 receptor as a neuroinflammatory modulator in experimental autoimmune encephalomyelitis

Oxymatrine ameliorates experimental autoimmune encephalomyelitis by rebalancing the homeostasis of gut microbiota and reducing blood-brain barrier disruption

Rapamycin Alleviates the Symptoms of Multiple Sclerosis in Experimental Autoimmune Encephalomyelitis (EAE) Through Mediating the TAM-TLRs-SOCS Pathway